AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 312 GBX -1.19% Market Closed
Market Cap: 159.9B GBX
Have any thoughts about
AstraZeneca PLC?
Write Note

During the last 3 months AstraZeneca PLC insiders bought 100.3k GBX , and have not sold any shares. The stock price has increased by 2% over this period (open performance analysis).

The last transaction was made on Apr 30, 2025 by Karen Knudsen , who bought 100.3k GBX worth of AZN shares.

Last Transactions:
Karen Knudsen
gbx+100.3k
Pascal Soriot
Chief Executive Officer
gbx+14.9m
Aradhana Sarin
Executive Director and Chief Financial Officer
gbx+6.2m
Tony Mok
Independent Non-Executive Director
gbx+190.2k
Michel Demar
Non-Executive Director
gbx+200.6k
Pascal Soriot
Chief Executive Officer
gbx+2m
Philip Broadley
Non-Executive Director
gbx+99.7k
Aradhana Sarin
Executive Director and Chief Financial Officer
gbx-1.5m
Michel Demar
Non-Executive Director
gbx+234k
Aradhana Sarin
Executive Director and Chief Financial Officer
gbx+4.9m
Aradhana Sarin
Executive Director and Chief Financial Officer
gbx-2.1m
Aradhana Sarin
Executive Director and Chief Financial Officer
gbx-1.2m
Andreas Rummelt
Non-Executive Director
gbx-989.5k
Aradhana Sarin
Executive Director and Chief Financial Officer
gbx+4.2m
Marc Dunoyer
Chief Executive Officer of Alexion, AstraZeneca's Rare Disease Group
gbx+4.2m
Nazneen Rahman
Non-Executive Director
gbx+19.9m
Philip Broadley
Non-Executive Director
gbx+99.9k
Euan Ashley
Chief Community Officer
gbx+36.1k
Michel Demaré
Non-Executive Chair
gbx+99.8k
Pascal Soriot
Chief Executive Officer
gbx+644.2k
Tony Mok
Independent Non-Executive Director
gbx+38.3k
Marc Dunoyer
Chief Executive Officer of Alexion, AstraZeneca's Rare Disease Group
gbx+3.4m
Pascal Soriot
Chief Executive Officer
gbx+7.1m
Tony Mok
Independent Non-Executive Director
gbx+48k
Michel Demaré
Non-Executive Chair
gbx+51.2k
Sheri Mccoy
Non-Executive Director
gbx+90.6k
Sheri Mccoy
Non-Executive Director
gbx+3.8k
Deborah Disanzo
Non-Executive Director
gbx+38.3k
Pascal Soriot
Chief Executive Officer
gbx+7.1m
Marc Dunoyer
Chief Executive Officer of Alexion, AstraZeneca's Rare Disease Group
gbx+3.4m
View All Transactions

During the last 3 months AstraZeneca PLC insiders bought 100.3k GBX , and have not sold any shares. The stock price has increased by 2% over this period (open performance analysis).

The last transaction was made on Apr 30, 2025 by Karen Knudsen , who bought 100.3k GBX worth of AZN shares.

Sold
0-3
months
0 GBX
0
3-6
months
0 GBX
0
6-9
months
0 GBX
0
9-12
months
0 GBX
0
Bought
0-3
months
1
100.3k GBX
3-6
months
2
21.1m GBX
6-9
months
4
2.5m GBX
9-12
months
No Insider Transactions
0
0 GBX

AstraZeneca PLC
Insider Trading Chart

AstraZeneca PLC
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

AstraZeneca PLC
Last Insider Transactions

Global
Insiders Monitor

AstraZeneca PLC
Glance View

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
14 794.82 GBX
Undervaluation 30%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top